Search

everythinglearnresearchcommunity

for

Search:↓

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tofacitinib taken by mouth helps treat hair loss in children.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.